What is the price target for AVRO stock?
8 analysts have analysed AVRO and the average price target is 2.04 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 1.4.
NASDAQ:AVRO • US05455M1009
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AVROBIO INC (AVRO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-12-18 | Mizuho | Downgrade | Buy -> Neutral |
| 2023-07-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-07-12 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-03-24 | Mizuho | Maintains | Buy |
| 2023-03-24 | Needham | Reiterate | Buy |
| 2022-12-08 | BTIG | Upgrade | Neutral -> Buy |
| 2022-05-17 | Needham | Maintains | Buy |
| 2022-05-11 | Barclays | Maintains | Overweight |
| 2022-01-06 | Mizuho | Maintains | Buy |
| 2022-01-05 | BTIG | Downgrade | Buy -> Neutral |
| 2022-01-05 | Needham | Maintains | Buy |
| 2022-01-05 | Barclays | Maintains | Overweight |
| 2022-01-05 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-11-19 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-10-12 | Morgan Stanley | Maintains | Overweight |
| 2021-07-16 | Morgan Stanley | Maintains | Overweight |
| 2021-06-15 | BTIG | Initiate | Buy |
| 2021-05-27 | Needham | Maintains | Buy |
| 2021-05-14 | Morgan Stanley | Maintains | Overweight |
| 2021-05-03 | SVB Leerink | Maintains | Market Perform |
| 2021-03-09 | Barclays | Initiate | Overweight |
| 2021-03-02 | Stifel | Initiate | Hold |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||
| EBITDA YoY % growth | -4.63M | -18.34M -296.11% | -45.86M -150.05% | -74.96M -63.45% | -119.02M -58.78% | -117.44M 1.33% | -103.99M 11.45% | -71.05M 31.68% | N/A -11.40% | N/A -29.64% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.63M | -18.39M -297.19% | -46.24M -151.44% | -75.81M -63.95% | -120.23M -58.59% | -118.84M 1.16% | -105.43M 11.28% | -71.667M 32.02% | N/A 28.79% | N/A -9.33% | N/A 93.05% | N/A 55.26% | N/A 29.41% | N/A 100.00% | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.68 16.63% | -3.31 -23.51% | -2.79 15.71% | -2.41 13.62% | -1.58 34.44% | N/A 69.01% | N/A 64.58% | N/A 76.47% | N/A -2,275.00% | N/A 120.00% | N/A 157.89% | N/A 53.06% |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 77.95% | -0.10 76.82% | -0.13 33.70% | -0.12 18.40% | -0.12 -50.00% | -0.12 -20.00% | -0.12 7.69% |
| Revenue Q2Q % growth | N/A | N/A | N/A | 4.094M | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.32M -3.75% | -20.4M 3.27% | -25.5M -164.88% | N/A | N/A | N/A | N/A |
All data in USD
8 analysts have analysed AVRO and the average price target is 2.04 USD. This implies a price increase of 45.71% is expected in the next year compared to the current price of 1.4.
AVROBIO INC (AVRO) will report earnings on 2024-08-08, after the market close.
The consensus EPS estimate for the next earnings of AVROBIO INC (AVRO) is -0.08 USD and the consensus revenue estimate is 0 USD.
The consensus rating for AVROBIO INC (AVRO) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.